Kornimate/medical-research-clean huggingface dataset:
postoperative pain in orbital disease and ocular tumor

Conditions: Postoperative Pain

Summary: the purpose of this study is to evaluate the postoperative pain after general anesthesia of orbital diseases and ocular tumor patients.

the purpose of this study is to evaluate patients diagnosed of orbital diseases or ocular tumor over 16 years old of the postoperative pain after general anesthesia , and to analyze the related factors of pain after operation.

Eligibility criteria:
inclusion criteria: * over 16 years old * diagnosed as orbital disease or ocular tumor * surgery under general anesthesia exclusion criteria: * any uncontrolled clinical problems

Keywords: postoperative pain general anesthesia
home air in agriculture: pediatric intervention trial

Conditions: Asthma in Children

Summary: this study seeks to reduce exposure to asthmagens in the homes of a community of latino children residing in an area of intense agricultural production in eastern washington by testing the effectiveness of an intervention (high efficiency particulate air filter- hepa portable room air cleaners) plus asthma education to reduce indoor measures of particulate matter, ammonia, improve clinically relevant measures of asthma health, and reduce biomarkers of inflammation.

over the course of five years, this project's specific aims are as follows: 1. build on a well-established community based participatory research program to engage community partners in the design, implementation and evaluation of this asthma intervention study. 2. conduct a year-long intervention study with longitudinal measurement of key asthmagen exposures and health outcome indicators with minimal participant burden. 3. develop and characterize evaluation metrics for the process, impact and outcomes of this project in achievement of the aims. 4. promote sustainable public health action via positive and transparent communications about the project to participants, local stakeholders, and state level policy makers through broad-based community outreach.

Eligibility criteria:
inclusion criteria: * eligibility criteria include male and female, poorly controlled asthma, likely to stay in the area over the course of the study, having only one residence, no smokers in the household and residential proximity to dairy operations/crop production (\<400 meters) determined by the telephone screening questionnaire. exclusion criteria: * prior participation in the asthma home visiting program, not from the northern third of the lower yakima valley, well controlled asthma, unlikely to stay in the are over the course of the study, smokers in the household, no residential proximity to dairy operations or crop production, having more than one residence and inability to communicate over the phone.

Keywords: latinx children agriculture hepa air cleaner home indoor/outdoor sampling coarse particulate matter fine particulate matter endotoxins antigens spirometry exhaled nitric oxide
effects of soft tissue mobilization on postsurgical adhesions, pain, lumbopelvic muscle functions, spinal mobility, and posture in postpartum women with caesarean section

Conditions: Postsurgical Adhesion

Summary: postpartum women with c-section receiving deep and superficial tissue mobilization would have better improvement on pain, lumbopelvic muscle functions, spinal mobility, and posture compare to the superficial tissue mobilization and control group


Eligibility criteria:
vaginal delivery inclusion criteria: * natural birth without c-section scar * postpartum more than 6 months * without any pain in the lumbopelvic region c-section inclusion criteria: * healed c-section scar \> six months * scar with or without pain both mode of delivery exclusion criteria: * active infection or infectious disease in the pelvis or abdomen * pain medications on days of measurements * skin irritation and inflammation at the site of the scar * currently pregnant or actively trying to get pregnant * history of radiation to the area * any fracture around spine and pelvis * any previous gynecologic and obstetric surgery
pharmacokinetic of doripenem and piperacillin/tazobactam in more than 120 kg critically ill patients

Conditions: Septic Shock

Summary: overweight patients are susceptible to develop acute complications when they are admitted in an intensive care unit (icu). severe infection can be associated with cardiovascular failure ('shock") and is associated with 35-50% mortality. one of the key issue to cure infection is to administer antibiotics. however, under dosing antibiotic is one of the main reason that explain treatment failure. there are very few data concerning particularities of antibiotic dosing in critically ill, overweight, patients. the aim of the present study is to describe the pharmacokinetic of two main antibiotics (doripenem and piperacillin/tazobactam) in both overweight and non overweight critically ill patients presenting a septic shock. the investigators hypothesis is that usual dose for those antibiotic may be accurate in non overweight patients but is not in overweight patients.

n=52 patients divided in 4\*13 patients (13 per antibiotic and per group, overweight or non overweight). overweight is defined by a weight over 120kg. antibiotic chosen by the intensivist in charge of the case. doripenem 1g/8h with a 4h iv infusion whatever the patient's weight. piperacillin/tazobactam 4g iv (1h) and then 16g/24h iv continuously whatever the patient's weight. piperacillin/tazobactam plasma dosage: after the first dose and then every 12h. doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value. usual plasma and urine samples for urea, creatinine, electrolytes, platelets and bilirubin each 24h. microbiology: bacterial identification and mic measurement with e-test

Eligibility criteria:
inclusion criteria: general: * patients in severe sepsis or septic shock defined by bone criteria (proved or very suspected infection with organ impairment and/or need of vasopressive agent to keep a mean arterial pressure more than 65mmhg) * patient requiring a treatment by study's antibiotics * informed consent signed * patient must be affiliated or beneficiary of a social medical insurance * participation of patient to the trial must be noted in the medical file specific to overweight patients: weight \> 120kg specific to no overweight patients: weight less than or equal to 120kg exclusion criteria: * pregnant women * under age patient minor * patient protected by law * known allergy to study's antibiotics

Keywords: septic shock overweight critically ill pharmacokinetic doripenem piperacillin-tazobactam
prevalence of non-alcoholic fatty liver disease among non-obese obstructive sleep apnea by using transient elastography

Conditions: Sleep Apnea, Obstructive; Fatty Liver

Summary: obstructive sleep apnea (osa) and non-alcoholic fatty liver disease (nafld) are both common diseases related to metabolic diseases with potential cardiovascular consequences and liver complications respectively. though studies show osa may take part in the progression of hepatic steatosis, the independent contribution of osa on liver fat accumulation is unknown. it is hypothesized that nocturnal intermittent hypoxia from osa is the main driver of nafld in non-obese osa patients. this study is to assess the effect of osa on nafld in non-obese patients.


Eligibility criteria:
inclusion criteria: * aged 18 years or more exclusion criteria: * underlying cause of liver disease * history of excessive alcoholic consumption (more than 30 g/day for men and 20 g/day for women) * secondary causes of hepatic steatosis (such as chronic use of systemic corticosteroids) * positive hepatitis b surface antigen, anti-hepatitis c virus antibody, or histological evidence of other concomitant chronic liver diseases.
hypercoagulation screening in cancer

Conditions: Healthy Blood Donors; Moli-sani Subjects; Cancer Patients

Summary: there is a complex, mutual relationship between cancer and thrombosis. indeed, the tumor has the capacity to activate the hemostatic system and this leads to an increased thrombotic risk in cancer patients. even in the absence of clinical manifestations, cancer patients are commonly characterized by hemostatic abnormalities, recognized only by laboratory testing, which define the 'hypercoagulable state'. of interest, hypercoagulation has been repeatedly reported to be associated with tumor progression and poor prognosis in various carcinomas. on the other hand, thrombotic event can represent the first signal of the presence of an occult tumor. these findings suggest that the coagulant pathway might play a role in the preclinical phase of cancer. the investigators hypothesize that a persistent, subclinical activation of the hemostatic system in an otherwise healthy subject, may predispose not only to thrombosis, but also to tumor formation and spreading. a major problem in primary cancer prevention is the lack of effective predictive markers of the disease. the hypercan is an ongoing prospective italian multicenter study organized around two tightly-interconnected research programs aiming to: 1_the assessment of thrombotic markers as a tool for cancer risk prediction in two large populations of healthy subjects, i.e. a group of healthy blood donors of bergamo and milano provinces and a subgroup of moli-sani subjects of the molise region; and 2_ the evaluation whether thrombotic markers and/or the occurrence of overt thrombosis (or disseminated intravascular coagulation) may be prognostic of cancer disease outcomes (i.e. overall survival, progression free survival in metastatic cancer, disease free survival in limited disease) in cancer patients with different types of solid tumors (i.e. breast, lung and gastrointestinal cancers). therefore, the assessment of cancer risk occurrence in healthy individuals might be useful for anticipation of cancer diagnosis. in addition, the results of this study might help to evaluate whether thrombotic markers may be prognostic of cancer outcomes independently of the disease extension.


Eligibility criteria:
blood donors_ inclusion criteria: * good health * signed informed consent. exclusion criteria: (considering 10-15 days from blood sampling) * inflammations/infections/fever; * recent vaccinations; * recent surgery; * anticoagulant therapy. cancer patients_ inclusion criteria: * with life expectation higher than 3 months; * patients with breast, lung or gastrointestinal tumors candidated for chemotherapy regimen; * ecog ps 0-2; * adeguate bone marrow and renal function; * signed informed consent. exclusion criteria: * acute medical illness; * terminal conditions or life expectancy less than 3 months; * under low molecular weight heparin at therapeutic dosage.

Keywords: hypercoagulation thrombosis cancer risk assessment cancer prognosis
evaluation of fibrin sealant 2 in retroperitoneal or intra-abdominal surgery

Conditions: Blood Loss, Surgical

Summary: a comparison of fibrin sealant 2 versus surgicel® as an addition to standard surgical practice in stopping mild to moderate soft tissue bleeding during retroperitoneal or intra-abdominal surgery.

the time it will take to stop bleeding will be measured and compared between patients who are treated with fibrin sealant 2 to those who are treated with surgicel®.

Eligibility criteria:
inclusion criteria: * male and female subjects requiring non-emergent retroperitoneal or intra-abdominal surgical procedures * presence of an appropriate soft-tissue target bleeding site (challenging bleeding site for which topical hemostatic adjuncts might typically be used) as identified intra-operatively by the surgeon * subjects must be willing to participate in the study and provide written informed consent exclusion criteria: * subjects undergoing emergency surgery * parenchymal or anastomotic bleeding sites will not be considered for randomization * subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure * subjects with known intolerance to blood products or to one for the components of the study product * subjects unwilling to receive blood products * subjects with known autoimmune immunodeficiency diseases (including known hiv * subjects who are known, current alcohol and/or drug abusers * subjects who have participated in another investigational drug or device research study within 30 days of enrollment * female subjects who are pregnant or nursing
use of virtual reality for pelvic external fixator removal

Conditions: Pelvic Fracture Pubic Rami Multiple - Unstable Closed

Summary: assessing the role of virtual reality in decreasing pain and improving patient satisfaction in outpatient removal of pelvic external fixator constructs.


Eligibility criteria:
inclusion criteria: * pelvis external fixator placed at study institution * external fixator placed for pelvic instability exclusion criteria: * infected pin or pins * loose pin or pins * psych history
effects of whole-body stretching exercise for reducing musculoskeletal pain and physical exertion among healthcare professionals

Conditions: Healthcare Professionals

Summary: purpose of the study:to investigate effect of whole-body stretching (wbs) exercise during lunch-break for reducing musculoskeletal pain and physical exertion among healthcare professionals

this study involved a single-blinded 2-arm randomized controlled trial (rct) to compare the effect of wbs exercise versus control group during lunch-break to reduce symptoms of wrmsds in healthcare professionals. sixty healthcare professionals were recruited from najran university hospital, saudi arabia. study objectives and procedure were properly explained and written informed consent was obtained at the beginning of the study. all the participants were randomly assigned into two equal groups a and b. group a were received the 30 minutes of whole body stretching class while group b were received an education program which includes ergonomic principles, wrmsds and their risk factors, as well as manual handling techniques were explained .

Eligibility criteria:
inclusion criteria: * full time healthcare professionals with more than one year of experience were eligible to participate exclusion criteria: * acute musculoskeletal symptoms (pain intensity on visual analogue scale (vas) \> 7)
can vitamin d treatment help treat moderate to severe atopic dermatitis in young children? the d-vex pilot study

Conditions: Atopic Dermatitis

Summary: vitamin d is known to have a regulatory influence on both the immune system and skin barrier function. studies in paediatric populations have found an inverse association of vitamin d levels and with both prevalence and severity of atopic dermatitis (ad). trials of vitamin d as a treatment for ad are limited in number and size. there has never been a placebo-controlled randomised controlled trial of stoss high dose versus daily standard dose for the treatment of ad. further, no trials have explored the presence of vitamin d pathway genes and response to treatment of ad. this pilot study will be used as a reference to determine outcomes and feasibility for undertaking a larger and more in depth definitive study.


Eligibility criteria:
inclusion criteria: * moderate to severe atopic dermatitis with a scorad ≥ 20 at baseline. * aged between 1 ≤ 12 years of age at the time of randomisation. * regularly ingest the recommended dietary intake (rdi) of calcium and plan to do so for the next 3 months * have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf. exclusion criteria: * use of vitamin d supplementation, including a stoss dose of vitamin d in the previous year, or daily supplementation in the past month * drink vitamin d fortified formula (all formulas) as the main milk intake * received oral steroids within the past 6 months * received oral immunosuppression in the past (cyclosporine, azathioprine, methotrexate) * received uv therapy in the past 12 months * have been fully formula fed within the past 6 months * ave renal or liver or gastrointestinal (e.g.: coeliac, inflammatory bowel disease) disease * receiving thiazide-type diuretics or anticonvulsant therapy * have ever been diagnosed with hypercalcaemia, hypertension or rickets * unable to provide consent without the aid of an interpreter * in the opinion of the investigator, are unable to follow the protocol

Keywords: vitamin d
retrospective study to analyze the efficacy and safety of trabectedin and pegylated liposomal doxorubicin (pld ) in the treatment of patients with platinum-sensitive recurrent ovarian cancer (roc), according to smpc

Conditions: Ovarian Epithelial Cancer Recurrent

Summary: retrospective study to analyze the efficacy and safety of trabectedin and pegylated liposomal doxorubicin (pld ) in the treatment of patients with platinum-sensitive recurrent ovarian cancer (roc), according to smpc.


Eligibility criteria:
inclusion criteria: * patients who have received at least one dose of trabectedin - doxorubicin pegylated for recurrent ovarian cancer according to smpc, between october 28, 2009 and october 31, 2014 and which have not been included in clinical trials where the imp was trabectedin. exclusion criteria: * patients with records unavailable (lost, empty or not recoverable).

Keywords: platinum-sensitive recurrent ovarian cancer
crp /albumin ratio and neutrophil lymphocyte ratio in predicting activity in ibd patients

Conditions: Inflammatory Bowel Disease (IBD)

Summary: this study aimed to assess the clinical utility of the nlr (neutrophil lymphocyte ratio) and crp albumin ratio in predicting activity of ibd patients in assiut university

ibd definition term for two conditions (crohn\&#39;s disease and ulcerative colitis) is a chronic idiopathic inflammatory disease affecting the large intestine. it is characterized by relapsing mucosal inflammation. the aim of treatment is to induce and maintain disease remission. assessing disease activity may help in optimizing the management of ibd patients. the neutrophil-to-lymphocyte ratio (nlr) is a simple index that can be calculated from the results of ordinary blood tests; it is calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count . as the nlr can reflect the systemic status of inflammation or immune response. the underlying mechanism that the nlr was a predictor of clinilcal relapse in uc patients with mucosal healing remains poorly understood. neutrophils induce cytotoxicity and inflammation in uc. a high nlr value may be due to high activity in uc and lowered mucosal barrier function, which may lead to the migration of neutrophils through the gut microbiota . crp is routinely used as a surrogate measure of intestinal inflammation and as a prognostic measure of nonresponse to medical therapy and colectomy in patients with ibd.

Eligibility criteria:
inclusion criteria: patients more than 18 years newly diagnosed as ibd - exclusion criteria: * patients not dm not cardiac failure not liver failure no malignancy

Keywords: crp/alb ratio n/l ratio
imatinib tdm in gist

Conditions: Gastrointestinal Stromal Tumors

Summary: imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (gist); however side effects can significantly hinder quality of life for our patients. this study will use therapeutic drug monitoring to improve quality of life and symptoms and assess how many patients maintain therapeutic levels. free drug levels and pharmokinetics of imatinib will also be monitored.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed gist with kit mutation or pdgfra mutation (non-d842v) * currently receiving imatinib initiated within the last 3 months or to be started in the next 1 month * prior systemic chemotherapy for other malignancy is allowed as long as it was completed within the past 6 months and there is no evidence of disease * age ≥18 years * ecog performance status of 0 or 1 * normal organ function exclusion criteria: * presence of pdgfra d842v mutation * known allergy to imatinib or allergic reactions to compounds of similar chemical or biologic composition to the study drug * concomitant anticoagulation with oral warfarin. * use of strong inhibitors or inducers of cyp3a or cyp3a4, drugs metabolized by cyp3a4 or cyp2d6 * uncontrolled intercurrent illness * concurrent malignancy
the 2-minute walk test in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: walking tests are widely used to assess functional capacity in different populations because of their ease of administration, interpretability and representativeness of activities of daily living.the aim of our study was to investigate the validity and reliability of the 2-minute walk test in hemodialysis patients.


Eligibility criteria:
inclusion criteria: * patients with end stage renal disease receiving hemodialysis * being clinically stable * being aged between 18-80 * volunteering to participate in this study exclusion criteria: * having a musculoskeletal problem that may affect functional capacity measurement * having had a cardiac event in the past 3 months

Keywords: hemodialysis
clinical,endoscopic and radiological assessment of portal hypertension in children with chronic liver diseases

Conditions: Portal Hypertension

Summary: portal hypertension is a significant cause of morbidity and mortality in children with chronic liver disease and portal vein obstruction. it results in severe complications such as ascites, hepatic encephalopathy and gastrointestinal variceal bleeding. (sutton et. al., 2018). esophageal varices is an important manifestation of portal hypertension that develops over time in children with chronic liver disease. the risk of esophageal varices hemorrhage increases depending on the underlying disease as well as the duration of the disease and the mortality rate as high as 5% - 20 % during patient follow up. invasive procedures such as gastroscopy are performed repeatedly to detect the presence and progression of esophageal varices. many non-invasive methods have been investigated to their efficacy in determining the presence of esophageal varices and the risk of complications in the presence of portal hypertension. (taşkın et.al., 2023). early diagnosis of portal hypertension is often difficult as it can be asymptomatic. during this stage, the patient may feel nothing except for mild fatigue or abdominal discomfort and therefore, patients mostly go undiagnosed (hartl et.al., 2021). (selicean et.al., 2021). however, it is worth noting that some of the results from medical investigation may be abnormal during this stage. these include abnormal liver function, abnormal routine blood examination (thrombocytopenia), and changes in the stiffness of the liver which can be found during ultrasound despite the patient being asymptomatic. ( mohanty et al., 2021). though the gold standard to diagnose portal hypertension is hepatic venous pressure gradient (hvpg) and a value more than 10 mmhg defines clinically significant portal hypertension (csph) ( man zhang et.al., 2022). since hvpg measurement is scarcely available and invasive, several non-invasive tests are used as surrogate markers of csph. amongst them, elastography techniques measuring liver stiffness (ls) and spleen stiffness (ss) are the extensively studied ones which can be done by elastography machines that can be attached to conventional ultrasound (usg) machines . amongst them, 2d-shear wave elastography (2d-swe) is the most recent one, and it assesses stiffness and related parameters by tracking shear waves propagated through a media. (sattanathan et.al., 2023).


Eligibility criteria:
inclusion criteria: - 1- age: \< 18 years 2- manifestations of hepatic disease like jaundice, hepatic encephalopathy, organomegally. 3- children previously diagnosed with chronic liver disease exclusion criteria: * 1- age: \> 18 years. 2- non compliant child during technique of elastography. 3- patient with ascites. 4- patient with portosystemic shunt surgery